Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gsk Plc ADR (NY: GSK )

33.96 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
35 36 Next >
Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
Via Benzinga
Intel and 9 Other Companies With Dividend Cuts in 2023
Intel announced that it would cut its dividend by a whopping 66%. Here are nine other companies that have also seen dividend cuts this year. 
Via InvestorPlace
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
GSK CEO Emma Walmsley On Beating Q4 Earnings
GSK came out with quarterly earnings of $0.64 per share. 
Via Talk Markets
GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine
Via Benzinga
My 3 Biggest Stock Market Predictions for March
These three trends will likely drive revenue and share prices. 
Via The Motley Fool
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among... 
Via Benzinga
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
Via Benzinga
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.  
Via Benzinga
Preview: GlaxoSmithKline's Earnings
Via Benzinga
Earnings Preview: GSK Q4 Earnings Expected To Decline
This drug developer is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -31.4%. 
Via Talk Markets
GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Dividend Income Update For January 2023
Without rehashing the wild ride we experienced in the market over the last few months, I could find comfort in one thing: my dividends (even if dividend cuts are on the table these days). Let's see how... 
Via Talk Markets
Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass
CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy from UMass Chan medical school. Additionally, Zhimeng Biopharma signed an agreement to out-license global... 
Via Talk Markets
FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting
Via Benzinga
FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer
Via Benzinga
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
February 2023 Stock Considerations
With a new trading month already in full swing, it is time to highlight some of my potential stock purchases. While the market had a nice bounce in recent months, there is still no shortage of stocks... 
Via Talk Markets
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
FDA Approves First Oral Treatment For Anemia Due To Chronic Kidney Disease
Via Benzinga
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
Two of the three companies easily beat sales and earnings expectations, but sales fell for the third. 
Via Investor's Business Daily
Earnings Scheduled For February 1, 2023
Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion. 
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs
Via Benzinga
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
But Moderna stock didn't move higher on the announcement. 
Via Investor's Business Daily
How Could GSK's RSV Vaccine Change its Valuation?
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future. 
Via MarketBeat
Exposures Product Safety
3 Penny Stocks That Could Make You Filthy Rich
These low-priced equities could deliver enormous returns for risk-tolerant shareholders. 
Via The Motley Fool
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock
Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market. 
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.